酪氨酸激酶抑制剂治疗中停药问题及根除慢性髓系白血病干细胞的治疗选择：第55届美国血液学会年会报道  

Report on recent discontinuation of tyrosine kinase inhibitors and alternative approaches to eradicating the chronic myeloid leukemia stem cells in the 55th ASH annual meeting

作　　者：陈英玉[1] 胡建达[1] 

机构地区：[1]福建医科大学附属协和医院福建省血液病研究所,福州350001

出　　处：《白血病．淋巴瘤》2014年第1期12-16,共5页Journal of Leukemia & Lymphoma

摘　　要：酪氨酸激酶抑制剂（TKI）的问世极大程度地改善了慢性粒细胞白血病（CML）的临床疗效,使众多CML患者从中获益,TKI治疗后达到长期完全分子生物学缓解（CMR）的患者停药是否安全,目前仍有争议.TKI治疗后清除残留白血病细胞、防止CML复发的解决方案,特别是针对CML干细胞的靶向治疗应用研究可能有望使CML患者达到长期无病生存,甚至治愈,因此成为人们近年来关注的重点.文章就第55届美国血液学会（ASH）年会上关于TKI停药选择以及清除CML干细胞的研究相关进展进行报道.Tyrosine kinase inhibitor （TKI） may significantly improve the treatment outcome in chronic myeloid leukemia （CML）.It is the most frequent question about whether the patients with durable complete molecular response （CMR） can safely discontinue TKI treatment without relapse.This has focused attention on the strategies to eradicate residual CML cells,especially the CML stem cells,which should result in long term leukemia-free survival and permanent cure.Here,the progress on discontinuation of TKI therapy and alternative approaches to eradicating CML stem cells in the 55th ASH annual meeting is reviewed.

关 键 词：白血病 髓样 慢性 酪氨酸激酶抑制剂 停药 干细胞 美国血液学会年会 

分 类 号：R733.72[医药卫生—肿瘤]